1137 related articles for article (PubMed ID: 25516477)
21. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
Wu G; Li H; Fang Q; Zhang J; Zhang M; Zhang L; Wu L; Hou X; Lu J; Bao Y; Jia W
Sci Rep; 2017 Jul; 7(1):5095. PubMed ID: 28698650
[TBL] [Abstract][Full Text] [Related]
22. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
23. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
25. Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.
Inagaki T
Front Endocrinol (Lausanne); 2015; 6():147. PubMed ID: 26441837
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
Zhao C; Liu L; Liu Q; Li F; Zhang L; Zhu F; Shao T; Barve S; Chen Y; Li X; McClain CJ; Feng W
Mol Metab; 2019 Nov; 29():145-157. PubMed ID: 31668386
[TBL] [Abstract][Full Text] [Related]
27. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
28. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target.
Liu WY; Huang S; Shi KQ; Zhao CC; Chen LL; Braddock M; Chen YP; Feng WK; Zheng MH
Expert Opin Ther Targets; 2014 Nov; 18(11):1305-13. PubMed ID: 25077735
[TBL] [Abstract][Full Text] [Related]
29. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
30. Regeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach.
Kim SJ; Kim SJ; Hyun J; Kim HW; Jang JH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542065
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
Başaranoğlu M; Örmeci N
Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
[TBL] [Abstract][Full Text] [Related]
32. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
33. FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD.
Wang Z; Sun T; Yu J; Li S; Gong L; Zhang Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):351. PubMed ID: 38179757
[TBL] [Abstract][Full Text] [Related]
34. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.
Ferreira DM; Simão AL; Rodrigues CM; Castro RE
FEBS J; 2014 Jun; 281(11):2503-24. PubMed ID: 24702768
[TBL] [Abstract][Full Text] [Related]
35. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging.
Gong Z; Tas E; Yakar S; Muzumdar R
Mol Cell Endocrinol; 2017 Nov; 455():115-130. PubMed ID: 28017785
[TBL] [Abstract][Full Text] [Related]
36. Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21.
Gong Q; Zhang X; Sun Y; Shen J; Li X; Xue C; Liu Z
J Mol Med (Berl); 2022 Nov; 100(11):1587-1597. PubMed ID: 36102936
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress.
Schaap FG; Kremer AE; Lamers WH; Jansen PL; Gaemers IC
Biochimie; 2013 Apr; 95(4):692-9. PubMed ID: 23123503
[TBL] [Abstract][Full Text] [Related]
38. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
[TBL] [Abstract][Full Text] [Related]
39. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
Yilmaz Y
Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women.
Rodrigues MH; Bruno AS; Nahas-Neto J; Santos ME; Nahas EA
Gynecol Endocrinol; 2014 May; 30(5):325-9. PubMed ID: 24460502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
